A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis
A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis
The purpose of this study is to evaluate the safety and efficacy of elezanumab in participants with progressive Multiple Sclerosis (PMS).
Inclusion Criteria:
Exclusion Criteria:
Berkeley, California 94705-2017, United States
Carlsbad, California 92011-4213, United States
Aurora, Colorado 80045-2527, United States
Lutherville, Maryland 21093-6016, United States
Farmington Hills, Michigan 48334, United States
Owosso, Michigan 48867-2116, United States
Chaska, Minnesota 55318-4551, United States
St Louis, Missouri 63131-2322, United States
Vancouver, British Columbia V6T 1Z3, Canada
London, Ontario N6A 5A5, Canada